Biotechnology
Pharmaceutical
Health

Flexion Therapeutics

$11.54
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.96 (-7.68%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell FLXN and other stocks, options, ETFs, and crypto commission-free!

About

Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. Read More It offers products under the Zilretta brand. The company was founded by Michael D. Clayman and Neil Bodick in 2007 and is headquartered in Burlington, MA.

Employees
272
Headquarters
Burlington, Massachusetts
Founded
2007
Market Cap
474.33M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
612.83K
High Today
$12.47
Low Today
$11.49
Open Price
$12.44
Volume
340.39K
52 Week High
$29.10
52 Week Low
$10.98

Collections

Biotechnology
Pharmaceutical
Health
Top Movers
Therapy
Technology
2014 IPO
US

News

MarketBeatMar 11

Stock Price, News, & Analysis for Flexion Therapeutics

Press coverage about FLXN stock has been trending somewhat positive this week, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Flexion Therapeutics earned a daily sentiment score of 0.7 on InfoTrie's scale. They also assigned media headlines about th...

57
Yahoo FinanceMar 4

Flexion Therapeutics to Present at the Cowen 39th Annual Health Care Conference

BURLINGTON, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will present at the Cowen 39th Annual Health Care Conference in Boston, Massachusetts. Dr. Clayman is scheduled to present at 1:30 p.m. ET on Monday, March 11, 2019. To access the live webcast and subsequent archived recording of the presentation, please visit the Flexion website at http://ir.flexiontherapeutics.com . About Flexion Therap...

56
Seeking AlphaFeb 28

Flexion Therapeutics, Inc. (FLXN) CEO Michael Clayman on Q4 2018 Results - Earnings Call Transcript

Flexion Therapeutics, Inc. (NASDAQ:FLXN) Q4 2018 Earnings Conference Call February 28, 2019 4:30 PM ET Company Participants Scott Young - Vice President, Corporate Communications & Investor Relations Michael Clayman - Chief Executive Officer Dan Deardorf - Senior Vice President, Commercial Operations David Arkowitz - Chief Financial Officer. Conference Call Participants David Maris - Wells Fargo Randall Stanicky - RBC Capital Markets Gary Nachman - BMO Capital Markets Elliot Wilbur - Raymond James...

79

Earnings

-$1.43
-$0.75
-$0.06
$0.62
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 8, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.